While there are currently no FDA-approved pharmacological therapies for the treatment of cataracts, an eye drop demonstrated promising vision improvements in patients with early-stage cataracts in a phase 1/2 clinical trial.
The randomized, double-masked, placebo-controlled, multicenter trial, published in the American Journal of Ophthalmology, investigated a proprietary formulation of 2.6% ethylenediaminetetraacetic acid disodium with methylsulfonylmethane, also known as C-KAD (Livionex). The subgroup analysis included 41 eyes, 21 of which received one drop of C-KAD four times a day for 120